People because as we get older. d our immune systems deteriorate. This vaccine is different from the other 2 that weve been reporting on because it is made from a weakened version of the common cold virus found in chimpanzees, which is then modified to make sure that it cannot grow in humans is given in 2 doses. And so far is reporting a 99 percent efficacy rate. All participants have been gently generating neutralizing antibodies. So it is knocking out the virus in their bloodstream with no reported side effects. And that is very good news here because this is the vaccine that britain is betting on. It has bought 100000000 doses of it so far. And so we are eagerly awaiting the phase 3 result. Whats interesting is that initially this vaccine was one of the front runners, and we thought wed be getting results much earlier. But as we know in the last 10 days, the pfizer bio and tech and the madonna vaccines have pulled ahead and, and have shown that they are more than 90 percent effectiv
Of the American People and supporting our like minded allies and partners worldwide. The military leaders, u. S. Allies and senior figures in trumps republican policy have warned of the dangers of putting too many troops out before conditions are right. Others are extremely important here in the next couple of months. Not to have any earth shaking changes with regard to defense and foreign policy. I think a precipitous drawdown and either afghanistan or iraq would be a mistake. Lets get the view from iraq al jazeera, simona fulton, is in baghdad. The reduction of u. S. Troops in iraq to 2500. 00 is not that significant in light of the drawdown that already took place earlier this year. In january, there were 5000. 00 troops present in country that number was reduced to 3000 as of september. And of course, the political and security context that precipitated this reduction was rather complex. Back in january, we had the us assassination of iranian general custom still in miami, as well
The vaccine this year. And were looking forward to maybe about 500000000. 00 to a 1000000000. 00 this next year. But that is going to be a 247 operation. It will be not, wont solve this problem. Its going to require many vaccines as weve been saying for a while, but we ought to be able to do our part from here for. This is really important. A White House Correspondent kimberly health kit has boy, in terms of who gets this vaccine . Well, according to the target ministration, it will be most vulnerable populations that will be getting it 1st that includes the elderly and those with compromised immune systems. But also what we know is that in fact, this could be 1st, be distributed about 20000000. 00 doses as early as december and the top Infectious Disease specialist dr. Anthony found, she says in fact that this vaccine is what he says is as good as it gets. The virus is not going to stop and call a time out. While things change the virus is just going to keep going. The process is just
It has made a breakthrough in the hunt for a vaccine. But there are no says its drug in early tests. Sure. Its 94 percent effective. We have a lot of work ahead of us knowing the vaccine is going to be a fact. It is great news, but we still need to complete the regulatory process. The Company Hopes to have the 1st 20000000 doses ready to go before the end of the year, front line workers and those most at risk will be treated 1st before theres a bigger rule out. Thats led americas top corporate expert to warn people. They cant relax just yet. The virus is not going to stop and call a time out while, while things change the virus is just going to keep going. The process is just going to keep going. This is something that just is now going in the very, very strong right direction. President donald trump, who claimed that last weeks breakthrough announcement was delayed until after the election to damage him politically. Struck a different tone with the new vaccine tweeting out that histor
Newshour, meeting with senator mark warner, who needs no introduction, chairman of the Senate Committee on intelligence. Ill be presiding over this discussion. Kenneth a moscow lecture. This is an annual lectureship that honors the memory of kenneth a. Moscow, longtime member of the council with a distinguished career in the Intelligence Community. Further details on his life and many professional accomplishments can be found in the booklet that you have at your seat. I do want to extend a special welcome to the members and guests of the moscow family who are here with us today, seated at the center table. Welcome to you. So, without further ado, ill just say i will invite senator warner. He will speak for about ten minutes, then ill have the opportunity to ask him questions for about 20 minutes and then at 1 00, we will open it up for questions for members. Without further ado, senator mark warner. Thank you for that introduction, judy. Looking forward to our discussion. That is, abou